# GLP-1 drug medical and economic impact > Live situation record from CLSTR: https://clstr.news/situations/glp-1-drug-medical-and-economic-impact > Updated: 2026-09-05T14:56:43.000Z. Sources: 5. Developments: 2. GLP-1 receptor agonist drugs, including semaglutide (the active ingredient in Ozempic), are significantly impacting the treatment of obesity, diabetes, and various cardiovascular and kidney diseases. These medications have driven massive market value increases for manufacturers such as Novo Nordisk and Eli Lilly, adding an estimated $1 trillion in value since 2021. Semaglutide functions by mimicking a natural hormone to stimulate insulin secretion, inhibit glucagon, slow gastric emptying, and reduce hunger by acting on the brain’s appetite centers. While primarily intended for metabolic disorders, its efficacy in weight loss has led to high demand, with clinical studies indicating users may lose 15% or more of their total body mass. Research is currently expanding into the potential use of these drugs for Alzheimer’s disease and drug addiction. The widespread adoption of these treatments is expected to have broad economic and societal implications as they become more accessible. ## Timeline ### 2026-09-05: Ozempic: mechanism, uses, and weight loss effects Ozempic, containing semaglutide, is a GLP-1 receptor agonist used for diabetes that has gained fame for its effectiveness in significant weight loss by regulating insulin and appetite. 2 sources. https://clstr.news/cluster/ozempic-mechanism-uses-and-weight-loss-effects ### 2026-08-27: GLP-1 drugs transform treatment for obesity and diabetes GLP-1 drugs like Ozempic are revolutionizing treatments for obesity and diabetes, driving massive market growth for Novo Nordisk and Eli Lilly while sparking discussions on celebrity usage. 3 sources. https://clstr.news/cluster/glp-1-drugs-transform-treatment-for-obesity-and-diabetes --- Cite as: GLP-1 drug medical and economic impact. CLSTR, https://clstr.news/situations/glp-1-drug-medical-and-economic-impact